MetaMax, Ltd
Biotechnology - , ,
MetaMax, Ltd Employees
MetaMax, Ltd Details
MetaMax, Ltd is a private biotech company founded in 2010 with the goal of developing and marketing innovative biopharmaceutical drugs that target most prevalent and dangerous systemic diseases. MetaMax has been financed by Maxwell Biotech Venture Fund, is Skolkovo resident and takes part in Technology Platform "Medicine of the Future". MetaMax's first product – MM-D37K – is an intravenously administered chimeric peptide to treat colorectal cancer. Preclinical proof-of-concept studies showed the agent's promising therapeutic activity against various cancer models (in vitro and in vivo) and presented evidence about additive and cumulative effect of MM-D37K and standard chemotherapeutic agents (in vitro).Development of MM-D37K has progressed to the stage of preparing the set of documents to initiate 1/2a clinical trials.
